Long-Term Treatment Experience with Aflibercept

EP: 1.Overview of Anti-VEGF Treatments for AMD and DME

EP: 2.Barriers to Optimal Treatment Outcomes

EP: 3.Patient and Cross-Care Education Strategies for AMD and DME

EP: 4.Real-World Long-Term Safety Data of Anti-VEGF Agents

EP: 5.Treat and Extend Strategy for Anti-VEGF Injections

EP: 6.Markers of Disease Progression in nAMD Patients

EP: 7.Significance of SRF vs IRF in nAMD

EP: 8.Current Treatment Options for nAMD

EP: 9.Managing Suboptimal Responders to Anti-VEGF Treatment

EP: 10.Applying CATT Study Results in Real World

Now Viewing

EP: 11.Long-Term Treatment Experience with Aflibercept

EP: 12.Treat and Extend Strategy for Aflibercept

EP: 13.Prospective Therapies and Treatment Strategies for nAMD

EP: 14.Unique Challenges of DME Treatment

EP: 15.Key Findings of Protocol T Study

EP: 16.Key Findings of DRCR Protocol AC Study

EP: 17.Step Therapy for Patients With DME

EP: 18.Efficacy of Faricimab in Clinical Trails

EP: 19.High Dose Aflibercept as Emerging Therapy for Retinal Diseases

EP: 20.Other Emerging Retinal Disease Therapies

EP: 21.Emerging Gene Therapies for Retinal Diseases

EP: 22.Final Thoughts on Retinal Disease Treatments and Outcomes

Transcript

Ehsan Rahimy, MD: Aflibercept has been the market leader for some time—well over a decade. Jon, what do we know about the long-term real-world efficacy and the safety of aflibercept?

Jonathan Jonisch, MD: We touched on this before. We’re fortunate in our community that we’ve had patients being treated with anti-VEGF therapy repeatedly, year after year, for over 20 years. The eye does remarkably well, and the patients remain largely very compliant. Systemically, we haven’t had major red flags. The bar is set high, and aflibercept has taken the lead since it was approved about 12 years ago. [It has] rapidly gained market share and has been the leader for the last 10 years. The bar is set high for newer medicines because of how safe and effective it is over a wide course of disease.

The convenience that we have in our clinic with prefilled syringes has come such a long way from where we started that so many of our patients are being extended way longer than a month. [Sometimes it’s 2, 3, or 4] months, as we alluded to. The eye seems to tolerate it, and the body seems to tolerate it. It’s that anti-VEGF ceiling that we’d all like to break through and see better long-term visual gains across a number of our diseases. But from a durability point of view, the newer medications have to prove to be more durable than aflibercept in order to knock it off the mountain.

Transcript edited for clarity.